MASH and Liver Fibrosis: Clinical Trials to Watch — VialBase Research

Summary

This 2026 Trial Watch review from Med journal summarizes the evolving drug development landscape for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH). It highlights semaglutide’s conditional FDA approval for MASH alongside resmetirom, noting that both received approval based on histological endpoints (MASH resolution without worsening fibrosis) rather than clinical outcomes.

Key Findings

• Semaglutide demonstrated MASH resolution in ~59% of treated patients vs ~17% placebo in Phase 2b data
• Conditional FDA approval granted for MASH indication — full approval pending long-term outcome data
• Resmetirom (thyroid hormone receptor beta agonist) also conditionally approved — complementary mechanism
• No approved therapy exists for MASH with established cirrhosis
• Full approval pathway requires demonstration of reduced major adverse liver outcomes (decompensation, liver transplant, liver-related death)
• Multiple promising targets in pipeline: FGF21 analogs, pan-PPAR agonists, combination approaches

Relevance to Semaglutide

This study documents semaglutide’s expansion beyond weight management and T2D into hepatology. The MASH indication represents a significant commercial and clinical expansion — MASH affects an estimated 5-6% of the global adult population and is a leading cause of liver transplant. Semaglutide’s mechanism (weight loss + direct hepatic effects via GLP-1R) addresses MASH from multiple angles. The conditional approval pathway is notable — it demonstrates FDA’s willingness to use surrogate endpoints for metabolic disease indications.

Citation

Zhang X, Wong VW. MASH and liver fibrosis: Clinical trials to watch. Med. 2026;7(4):101069. doi:10.1016/j.medj.2026.101069.

See Also

• Parent compound: Semaglutide